Precigen, Inc. (PGEN)
NGS · Common · CUSIP 74017N105
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for PGEN and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
74017N105 (prev. 46122T102 )
Market Cap
Mid Cap
IPO
8/8/2013 · $16.00/share
Previous Symbol
XON (changed 2/3/2020)
Previous Name
Intrexon Corp.
Business: Precigen, Inc. is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and Environment to create biologically based products that improve quality of life and the health of the planet. At present rates of global industrialization and population growth, food and energy supplies and environmental and healthcare resources are becoming scarcer. Intrexon’s leading Better DNA approach to synthetic biology has the potential to provide new, more effective and sustainable solutions to address these challenges. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Working with key collaborators, Intrexon seeks to develop high value applications that can bring better medicines to more people, alleviate shortages of essential nutrients, develop renewable fuels and other resources, and protect the environment.
Notes: January 30, 2020, the Corporation filed its amended and restated Amended and Restated Articles of Incorporation, as amended (as amended and restated, the “Articles of Incorporation”) with the State Corporation Commission of the Commonwealth of Virginia, to change the name of the Corporation from Intrexon Corporation to Precigen, Inc.

Company Contact

CEO
Randal J. Kirk
CFO
Rick Sterling
Headquarters
20374 Seneca Meadows Parkway, Germantown, MD 20876
Phone
301-556-9900
Investor Relations
Steven Harasym · 301-556-9850 · investors@precigen.com
Email Form
Request Form »
SEC EDGAR Filings
View filings »